

- 29. (NEW) A method of enhancing expression of a gene, expression of which is activated by phosphorylated Smad 1, comprising contacting a cell which express ALK-1 and which is capable of expressing said gene with TGF- β which activates phosphorylation of Smad-1.

30. (NEW) A method of enhancing expression of a gene, expression of which is activated by phosphorylated Smad 1, comprising contacting a cell which express ALK-1 and which is capable of expressing said gene with a portion of TGF- β sufficient to bind to ALK-1 to activate phosphorylation of Smad 1.

31. (NEW) A method for identifying a gene whose activation is effected by phosphorylated Smad 1, comprising

E2 (1) contacting a first sample of cells, which express ALK-1 and which express and phosphorylate Smad 1, with TGF- β , or a portion of TGF- β sufficient to bind to ALK-1,

(2) removing transcripts of said cell sample, and

(3) comparing said transcripts to transcripts to a second sample of cells not contacted with TGF- β , or a portion of TGF- β sufficient to bind to ALK-1, wherein differences therebetween are transcripts of genes whose activation is affected by phosphorylation of Smad

1. -

REMARKS

Applicants have cancelled claims 21-24, 26 and 28 without prejudice and expressly reserving the right to pursue any of the cancelled subject matter in subsequent applications.

The Examiner contends that applicants have not fully complied with the sequence listing rules as set forth in 37 C.F.R. § 1.821-1.825. Applicants submit concurrently herewith a replacement sequence listing in paper and computer readable form and request that it be entered.